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Introduction: The impact of coronary artery disease (CAD) on outcomes after transcatheter
aortic valve implantation (TAVI) has not been clarified. Furthermore, less is known about
the indication and strategy of revascularization in these high risk patients.
Aims: This study sought to determine the prevalence and prognostic impact of CAD in
patients undergoingTAVI, and to assess the safety and feasibility of percutaneous coronary
intervention (PCI) before TAVI.
Methods: Patients with severe aortic stenosis (AS) undergoing TAVI were included into a
prospective single center registry from 2007 to 2012. Clinical outcomes were compared
between patients with and without CAD. In some patients with CAD, it was decided to
perform elective PCI before TAVI after decision by the Heart team. The primary endpoints
were 30-day and 2-year all-cause mortality.
Results: A total of 91 consecutive patients with mean age of 79±9 years (52% men)
underwent TAVI with a median follow-up duration of 16 months (interquartile range of
27.6 months). CAD was present on 46 patients (51%). At 30-day, the incidences of death
were similar between CAD and non-CAD patients (9 and 5%, p= 0.44), but at 2 years
were 50% in CAD patients and 24% in non-CAD patients [crude hazard ratio with CAD,
2.2; 95% confidence interval (CI), 1.1–4.6; p=0.04]. Adjusting for age, gender, left ventric-
ular ejection fraction, and glomerular filtration rate, the hazard of death was 2.6-fold higher
in patients with CAD (95% CI, 1.1–6.0; p=0.03). Elective PCI before TAVI was performed
in 13 patients (28% of CAD patients). There were no more adverse events in patients who
underwent TAVI + PCI when compared with those who underwent isolated TAVI.
Conclusion: In severe symptomatic AS who underwent TAVI, CAD is frequent and
adversely impacts long-term outcomes, but not procedure outcomes. In selected patients,
PCI before TAVI appears to be feasible and safe.
Keywords: coronary disease, aortic valve stenosis, transcatheter aortic valve implantation, percutaneous coronary
angioplasty intervention, prognosis
INTRODUCTION
Coronary artery disease (CAD) affects 25–50% of patients with
severe aortic stenosis (AS) who undergo surgical aortic valve
replacement (SAVR). (1) Its presence negatively impacts the
periprocedural and long-term outcomes after SAVR. However,
improved long-term survival has been reported in patients with AS
and CAD who underwent combined SAVR and CABG compared
with those receiving isolated SAVR (2). Based on these findings,
current guidelines recommend bypass surgery to all significant
stenosis at the time of SAVR (3, 4).
The prevalence and impact of CAD on outcomes after tran-
scatheter aortic valve implantation (TAVI) have not been fully
delineated. Published studies specifically addressing this issue are
sparse and controversial (5–8). Moreover, the only randomized
clinical trial that compares SAVR with TAVI excluded patients
with CAD requiring revascularization (9). Consequently, the orig-
inal TAVI protocol precludes that significant CAD must be treated
by percutaneous coronary intervention (PCI) before TAVI, and
that CAD not treatable by PCI should be considered a formal
contraindication for TAVI (4, 10). However, it is unknown if
revascularization in the high-risk population referred to TAVI
is associated with similar benefits to those observed in patient
referred to SAVR. Furthermore, performing PCI in a patient with
severe AS can be problematic; thus, the risks of PCI in the set-
ting of AS are unknown (11). Since CABG is the primary mode
of revascularization in patients with CAD and moderate to severe
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AS, PCI has been limited to patients with AS who presented with
acute coronary syndrome. Furthermore, the safety of TAVI has
just been investigated isolated from concomitant revascularization
procedures (12, 13).
The aims of the present study were to determine the prevalence
of CAD and its impact on procedural outcomes and long-term
survival in patients undergoing TAVI, and to assess the safety and
feasibility of PCI before TAVI.
MATERIALS AND METHODS
PATIENT POPULATION
Consecutive patients with symptomatic AS undergoing TAVI at
Centro Hospitalar de Vila Nova de Gaia were enrolled in a
prospective registry from August 2007 to October 2012. The study
complied with the declaration of Helsinki, and the registry was
approved by the local ethics committee. All the patients pro-
vided written informed consent to participate in our registry with
prospective follow-up assessment.
Initial assessment included clinical evaluation by the Heart
Team, transthoracic and transesophageal echocardiography, inva-
sive coronary angiography, and computed tomography of the
aorta, iliac, and common femoral arteries. In all patients, the
logistic European System for Cardiac Operative Risk Evaluation
(EuroSCORE), EuroSCORE 2 (14), and the Society of Thoracic
Surgeons Predicted Risk of Mortality (STS-PROM) (15) were cal-
culated. Patients were excluded from the analysis if the procedure
was considered unsuccessful according to criteria in the Valve Aca-
demic Research Consortium (VARC-I) guidelines (16). TAVI was
performed using the Medtronic CoreValve system (Medtronic,
Minneapolis, MN, USA) or the Edwards SAPIEN valve (Edwards
Lifesciences, Irvine, CA, USA) by transfemoral, transapical, or
transsubclavian approach according to the instructions for use
and as previously described (9, 12). Devices and access site were
selected by anatomical and technical features. In some patients,
it was decided to perform elective PCI before TAVI either in a
planned intervention prior to TAVI (staged PCI) or at the time of
TAVI (concomitant PCI). In cases of concomitant PCI, patients
first underwent PCI followed by TAVI in the same session. Revas-
cularization strategy was based on the amount of myocardium
at risk, which was estimated integrating the visual assessment
of the coronary anatomy, the presence of wall motion alter-
ation in the echocardiogram, and history of prior myocardial
infarction. On the day before TAVI, patients undergoing iso-
lated TAVI were medicated with 250 mg of aspirin and 300 mg
of clopidogrel, and the patients undergoing concomitant PCI
were medicated with 250 mg of acetylsalicylic acid and 600 mg
of clopidogrel. Procedural anticoagulation was obtained with a
heparin bolus of 70 IU/kg, aiming for an activated clotting time of
250–300 ms.
ANGIOGRAPHIC ANALYSIS
For the purpose of this study, baseline coronary angiographies
were analyzed by two experienced interventional cardiologists.
CAD group included patients with at least one lesion on the epi-
cardial coronary arteries with≥50% diameter stenosis or patients
who had been submitted to coronary revascularization by PCI or
CABG before AS diagnosis.
STUDY END POINTS AND DEFINITIONS
Primary end points included 30-day and 2-year all-cause mor-
tality. Prespecified secondary end points included mortality from
cardiovascular causes, myocardial infarction, stroke, acute renal
injury, vascular complications, bleeding, new onset atrial fibril-
lation, and pacemaker implantation. In a retrospective analysis
of neurologic events, major stroke was defined by a score of at
least 2 on the modified Rankin scale (which ranges from 0 to 6,
with higher scores indicating greater disability). All events were
adjudicated according to the VARC I definitions (16) by a clinical
event committee consisting of invasive cardiologists and cardiac
surgeons. Patients were followed during the index hospitalization
and at 30 days, 6 months, 1 year, and yearly thereafter.
STATISTICAL ANALYSIS
Patients were stratified into two groups according to the pres-
ence or absence of CAD. Baseline characteristics and clinical out-
comes were compared between groups. Continuous variables were
described using the mean± SD if normally distributed or median
and interquartile range (IQR) when non-normally distributed.
Student’s t -test was used for the comparisons between continuous
variables if normally distributed, and Mann–Whitney U in cases
of non-normally distributed variables. Categorical variables were
described using relative frequencies, and compared between CAD
and non-CAD patients using the Chi-square test or Fisher exact
test when appropriate. Clinical outcomes at 30 days and 2 years
were expressed as counts or incidence rates computed according to
Kaplan–Meier analysis. Hazard ratios were derived from Mantel-
Cox log-rank for all-cause mortality. Clinical outcomes at 30 days
and 2 years were also compared between patients with and with-
out CAD. A Cox multivariate regression analysis was performed
to determine adjusted hazard ratio of death between groups. We
estimated that a sample size of 91 patients (controls ratio of 0.49)
allowed the detection of an hazard ratio difference of 0.5 for the
primary end point with a type II error of 20% and a significance
level of 5% (two-sample comparison of survivor functions log-
rank test by the Freedman method). To assess feasibility and safety
of PCI before TAVI, the clinical outcomes at 30 days were com-
pared between patients with CAD who underwent isolated TAVI
and TAVI+PCI. A p-value<0.05 was considered to indicate a sta-
tistically significant difference. Statistical analysis was performed
using SPSS 19.0 for Windows (SPSS, Inc., Chicago, IL, USA).
RESULTS
A total of 91 consecutive patients (52% men) with mean age of
79± 9 years underwent TAVI. CAD was present on 46 patients
(51%). Among CAD group, 26 patients (48%) had prior revascu-
larization, 8 patients (17%) had “de novo” significant CAD, and
13 patients (28%) needed elective PCI before TAVI (Figure 1).
Scheduled follow-up was completed in all patients with a median
duration of 16 months (IQR of 27.6 months, Quartile 25 of
5.6 months).
BASELINE CHARACTERISTICS
Baseline clinical and echocardiographic characteristics are sum-
marized in Table 1. Patients with CAD were more frequently
men (67 and 33%, p< 0.01), hypertensive (89 and 67%,
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FIGURE 1 | Study flowchart. CAD, coronary artery disease; PCI,
percutaneous coronary intervention; TAVI, transcatheter aortic valve
implantation. TAVI+PCI combined procedure including both TAVI and PCI.
p= 0.01), dyslipidemic (76 and 53%, p= 0.02), had worse
renal function, [glomerular filtration rate (GFR): 50± 19 and
64± 33 mL/min/m2, p= 0.02], and left ventricular systolic func-
tion (left ventricular ejection fraction, LVEF: 47± 10 and 53± 9%,
p< 0.01 with a prevalence of LV dysfunction in CAD of 46% and
in non-CAD of 20%, p= 0.021). Mean EuroScore 2 was signifi-
cantly higher in CAD group (9± 4 and 5± 4, p< 0.01). Patients
with CAD had similar age, aortic valve area, and functional class
of heart failure when compared with those without CAD.
CLINICAL OUTCOMES
Clinical outcomes at 30 days and 2 years after TAVI with or with-
out CAD are presented in Table 2. Time-to-event curves for the
primary end point are displayed in Figure 2.
At 30 days, the primary end point was not statistically different
between patients with and without CAD (incidence of mortal-
ity with CAD: 9%; non-CAD: 5%, p= 0.44). The 30-day major
stroke (CAD: 5%; non-CAD: 2%,p= 0.52), life-threatening bleed-
ing (CAD: 18%; non-CAD: 15%, p= 0.32), and major vascular
complications (CAD: 10%; non-CAD: 11%, p= 0.44) were not
statistically different when comparing CAD and non-CAD groups.
The 2-year-mortality was 50% in CAD patients and 24% in
non-CAD patients (crude hazard ratio with CAD, 2.2; 95% con-
fidence interval [CI], 1.1–4.6; p= 0.04). Adjusting for age, gen-
der, hypertension, dyslipidemia, LVEF, and GFR, the hazard of
death was 2.6-fold higher in patients with CAD (95% CI, 1.1–6.0;
p= 0.03). Mortality from cardiovascular causes was also signif-
icantly higher in patients with CAD (hazard ratio with CAD
of 2.2; 95% CI from 1.2 to 4.6, p= 0.04). No differences were
found in cumulative incidence of the others secondary end points
(Table 2).
FEASIBILITY AND SAFETY OF PCI BEFORE TAVI
Procedural characteristics of PCI before TAVI were described in
Table 3. Elective PCI before TAVI was performed in 13 patients:
11 in a planned intervention (staged PCI ) in a median of 56 days
before TAVI, and 2 at the time of TAVI (concomitant PCI ). The
Table 1 | Comparison of baseline clinical, echocardiographic, and
procedural characteristics between CAD and non-CAD groups.
All
(n=91)
CAD groups p-Value
CAD
(n=46)
Non-CAD
(n=45)
Age (years) 79±9 79±7 78±7 0.283
Male gender, n (%) 47 (52) 32 (67) 15 (33) 0.001
STS-PROM score 6±5 7±5 6±5 0.559
EuroScore 2 7±5 9±4 5±4 0.004
Hypertension, n (%) 71 (78) 41 (89) 30 (67) 0.010
Dyslipidemia, n (%) 59 (65) 35 (76) 24 (53) 0.023
Diabetes, n (%) 35 (38) 19 (41) 16 (36) 0.573
Class III or IV NYHA, n (%) 61 (67) 30 (65) 31 (69) 0.710
Prior PCI, n (%) 8 (9) 8 (17)
Prior CABG, n (%) 16 (19) 16 (35)
CVD, n (%) 21 (23) 13 (28) 8 (18) 0.235
PAD, n (%) 35 (17) 21 (46) 14 (31) 0.154
COPD, n (%) 39 (43) 17 (37) 22 (49) 0.250
GFR (mL/min/m2) 58±28 50±19 64±33 0.012
Renal dysfunction, n (%) 60 (66) 37 (82) 23 (50) 0.008
AF, n (%) 29 (32) 15 (33) 14 (31) 0.878
Permanent pacemaker, n (%) 7 (8) 3 (7) 4 (9) 0.672
Echocardiografic evaluation
AVA, cm2 0.6±0.1 0.6±0.2 0.6±0.1 0.850
Mean AV gradient (mmHg) 51±13 50±13 52±13 0.505
LVEF (%) 50±10 47±10 53±9 0.006
LV dysfunctiona, n (%) 30 (33) 21 (46) 9 (20) 0.0210
Moderate or severe MR, n (%) 5 (7) 1 (2) 4 (9) 0.125
Procedure features
Transarterial access, n (%) 87 (96) 44 (96) 43 (96) 0.982
Transapical access, n (%) 4 (4) 2 (4) 2 (4) 0.999
Medtronic/coreValve, n (%) 79 (87) 38 (83) 41 (91) 0.231
Edwards SAPIEN, n (%) 12 (13) 8 (17) 4 (9) 0.072
Results are presented as mean±SD.
p-Values shown compare CAD and non-CAD groups.
AF, atrial fibrillation; AV, aortic valve; AVA, aortic valve area; CABG, coronary
arteries bypass graft; COPD chronic obstructive pulmonary disease; CVD cere-
brovascular disease; GFR, glomerular filtration rate; LVEF, left ventricular ejec-
tion fraction; MR, mitral regurgitation; NYHA, New York Heart Association; PAD,
peripheral artery disease; PCI, percutaneous coronary intervention; STS, Society
of Thoracic Surgeons.
aLeft ventricular systolic dysfunction was defined as ejection fraction lower than
50%.
most frequent (5 of 13 cases) PCI concerned patients with severe
stenosis of vein graft. Drug eluting stents were used in the major-
ity of cases (9 of 13 cases). There were no major adverse events
after PCI. Thirty-day all-cause mortality was similar between
patients treated with TAVI+PCI (17%) or isolated TAVI (10%)
(p= 0.296). Incidence of 30-day major stroke (p= 0.270), life-
threatening bleeding (p= 0.229), and major vascular complica-
tions (p= 0.229) did not differ between patients who underwent
TAVI+PCI or isolated TAVI (Figure 3).
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Table 2 | Clinical outcomes at 30 days and 2 years with or without CAD.
Outcome 30 days p–Value* 2 years p-Value*
CAD
n=46
Non-CAD
n=45
CAD
n=46
Non-CAD
n=45
No of patients (%) No of patients (%)
Death from all causes 4 (9) 2 (5) 0.446 17 (50) 9 (24) 0.042
Death from cardiovascular causes 2 (3) 1 (3) 0.890 10 (35) 3 (8) 0.038
Stroke or TIA 5 (11) 3 (7) 0.520 9 (20) 5 (15) 0.321
Myocardial infarction 0 0 1 (2) 0 0.160
Major vascular complications 5 (11) 4 (10) 0.441 6 (12) 4 (10) 0.448
Major bleeding 5 (11) 4 (10) 0.441 6 (12) 4 (10) 0.448
Acute renal lesion 6 (13) 4 (10) 0.580 7 (14) 5 (11) 0.652
NOAF 11 (30) 8 (20) 0.621 11 (30) 9 (23) 0.601
New pacemaker implantation 16 (34) 12 (27) 0.442 16 (34) 12 (27) 0.458
All percentages are Kaplan–Meier estimates at the specific time point and thus do not equal the number of patients divided by the total of number in the study group.
CAD, coronary artery disease; NOAF, new onset atrial fibrillation; TIA, transient ischemic attack.
*p-Values are for the between-group comparison of the frequency of the event at each time point.
FIGURE 2 |Time-to-event curves for the primary end point. Events were
calculated with the use of Kaplan–Meier methods and compared with the
use of a log-rank test. CAD, coronary artery disease; TAVI, transcatheter
aortic valve implantation.
DISCUSSION
This study showed that significant CAD is very frequent in patients
undergoing TAVI implantation and its presence adversely impacts
long-term outcomes, but not periprocedural outcomes. In selected
patients, PCI before TAVI appears to be feasible and safe.
CAD IS FREQUENT IN PATIENTS UNDERGOING TAVI
In our study, CAD was observed in more than half of patients
who underwent TAVI. The prevalence of CAD reported in the
few publications on this topic ranges from 49 to 75% (5–8). Var-
ious definitions of CAD had been used on the available literature
Table 3 | Procedural characteristics of elective PCI beforeTAVI.
TAVI+PCI n=13
Time to TAVI – daysa 40 (0–166)
Concomitant procedure, n (%) 2 (15)
Staged procedures, n (%) 11 (82)
Time to TAVI – daysa 56 (3–166)
Vessel, n (%)
LM 3 (23)
LAD 4 (30)
LCX 1 (8)
RCA 0
Vein graft 5 (39)
Stents per patient, n (%)
1 11 (84)
2 2 (15)
Drug eluting stents, n (%) 9 (75)
aResults are presented as median (range).
LAD, left descending artery; LM, left main, LCX, left circumflex artery; PCI, per-
cutaneous coronary intervention; RCA, right coronary artery; TAVI, transcatheter
aortic valve implantation. TAVI+PCI combined procedure including both PCI and
TAVI.
which could account, in part, for the differences in results. Mas-
son et al. (6) used a broad definition of CAD including patients
with prior revascularization or any coronary lesion of at least
50% in angiography, and as expected, they reported the higher
prevalence of co-existent CAD (6). Dewel et al. (5) defined CAD
as prior coronary revascularization excluding those with signif-
icant CAD treated medically. Despite the wide variety of CAD
definition, it seems common that in patients referred for TAVI,
the prevalence of CAD tends to be higher than SAVR series of
AS patients. This can be explained in part as consequence of
selection bias (i.e., older patients or previous CABG tend to be
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FIGURE 3 | Clinical outcomes at 30 days according to the Valve Academic Research Consortium (VARC) safety endpoints for patients who underwent
isolatedTAVI and elective PCI beforeTAVI. PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation.
more frequently refused for surgery and to undergo TAVI as an
alternative procedure).
CAD MANAGEMENT IN THE SETTING OF TAVI
The current 2014 guidelines for myocardial revascularization in
patients with stable CAD recommend to perform revasculariza-
tion only in cases with documented ischemia by non-invasive
imaging stress tests or invasive fractional flow reserve assessment
(FFR) <0.8 (17). However, in patients with symptomatic severe
AS and concomitant CAD, it remains indicated to revascularize all
the significant coronary stenosis visualized on the angiography by
CABG at the same time of SAVR (4), or by PCI at least 1 month
before TAVI (4, 10).
Detection of ischemia in patients with AS
In stable angina, Boden et al. showed that revascularization should
not be routinely performed in the presence of significant coronary
stenosis on angiography even in symptomatic patients (18). Fur-
thermore, FAME trials clearly demonstrate that diameter stenosis
is not a good marker of significance of disease and that revascu-
larization should be guided according to functional evaluation.
(19) Currently, it is possible invasively and non-invasively to iden-
tify myocardial ischemia; however, there remains many concerns
about the safety and diagnostic accuracy of cardiac stress tests in
patients with symptomatic severe AS.
A protocol of 6-min perfusion adenosine to assess myocardium
perfusion by SPECT in patients with severe AS showed to be safe
and diagnostically accurate for the presence of CAD (20). Recently,
dobutamine stress echocardiogram was helpful to assess severity
and to predict outcomes in patients with paradoxical low-flow
gradient AS with preserved ejection fraction referred to TAVI with
no major adverse effects. (21). Despite these data in favor of stress
tests safety in severe AS, its diagnostic value is unknown. Typically,
coronary artery flow reserve is impaired in AS, which may affect
the FFR cut-off reference value. (22) Moreover, in patients with
AS, left ventricular hypertrophy may be accompanied by intersti-
tial myocardial fibrosis starting at the subendocardial layers and
progressing toward replacement fibrosis. (23) These alterations
gradually affect left ventricular systolic and diastolic function,
which can lead to segmental kinetic alterations and myocardial
perfusion defects misclassifications in stress echocardiogram and
cardiac magnetic resonance imaging (CMRI).
Impact of ischemia on periprocedural and long-term outcomes after
TAVI
The rationale of revascularization before TAVI is based on the
belief that worsening of myocardial ischemia during rapid ven-
tricular pacing could occur in the presence of non-revascularized
CAD. However, since TAVI is a less invasive procedure than surgical
replacement, the procedure advantages of revascularization may
be more discrete than in SAVR. Furthermore,beyond CAD,various
hypotheses exist on the underlying mechanisms of periprocedural
myocardial injury in patients undergoing TAVI. These include
global myocardial ischemia due to extreme hypotension, direct
trauma during balloon inflation or prosthesis placement, and
coronary embolization of aortic valve debris. In a recent study, Kim
et al. determined the incidence and degree of ischemic myocar-
dial damage using CMRI and myocardial biomarkers in patients
undergoing TAVI; these authors found that new late myocardium
gadolinium enhancement (LGE) after TAVI was observed in a
notable proportion of patients (18%), but the majorly was small
size, subendocardial, or intramural, and multifocal suggesting
embolic origin. Interestingly, no correlation was found between
pre-existing coronary stenosis and the localization of new infarc-
tions (24). In our study, CAD did not associate with higher risk of
30-day mortality. Our results are closer to those of Masson et al.
(6), who observed similar 30-day mortality in patients with and
without CAD (11.5 vs. 6.3%, p= 0.39), and those of Gautier et al.
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(7), who did not demonstrate influence of CAD on 30-day mortal-
ity after TAVI. In The PARTNER US Trial, a subgroup analysis did
not show any significant interaction between the presence of prior
coronary revascularization and the effect of TAVI treatment on 30-
day mortality (9, 12). Consistent with these results, our findings
suggest that CAD has limited impact on the periprocedural risk
of TAVI. Contrary, Dewey et al. (5) showed a 30-day mortality 10-
fold higher among CAD compared to non-CAD patients (13.1 vs.
1.2%, p= 0.002). In this study, CAD group only included patients
with previous PCI or CABG. This restrictive CAD definition could
justify the higher mean STS predicted risk of mortality (13± 4) of
this population when compared with our CAD patients (7± 5).
Few studies are available on the long-term effect of CAD on
TAVI outcomes. Congruent with our findings, incomplete revas-
cularization was demonstrated to be an independent predictor of
decreased left ventricular recovery and was associated with higher
1-year mortality. (25) A comparable result was found when the
SYNTAX score was applied for the evaluation of the revascular-
ization status, but not when significant CAD was defined using a
visual estimation alone. (26) By contrast, a revascularization strat-
egy selection by a dedicated Heart Team was reported to provide
a similar long-term prognosis independently of the revasculariza-
tion status; the presence of incomplete coronary revascularization
did not worsen the 1-year survival (27). Similarly, Masson et al. (6)
showed no impact of CAD on 1-year mortality after TAVI. In the
Multicentre Canadian Experience, coronary status was not predic-
tor of cumulative late mortality after TAVI, as well (28). Despite
differences between CAD definition and revascularization status,
it has been speculated that the benefit of revascularization on sur-
vival improvement may be mitigated by a shorter life expectancy
and less active lifestyle in the older TAVI population.
Safety of PCI in patients undergoing TAVI
Goel and colleagues, in a systematic analysis comparing the out-
comes after PCI in 254 patients with severe AS with 508 patients
without AS, found that the 30-day mortality was similar between
patients with or without AS (11). This finding led the authors
to speculate that PCI could be an alternative in the manage-
ment of CAD in patients considered to TAVI. However, a new
pattern of complications must be considered when performing
PCI and TAVI (28–31). PCI before TAVI may increase bleeding
and vascular complications due to dual antiplatelet therapy and
could also increase the risk of stroke and contrast-related kid-
ney injury in this elderly co-morbid group of patients. Data on
safety and feasibility of the strategy of PCI before TAVI are limited
to a single-center encouraging experience (29, 30). Abdel-Wahab
M et al. evaluated the 30-day and 6-month safety of PCI before
TAVI; the VARC-defined combined safety end point (11vs. 13%,
p= 0.74) did not differ between patients submitted to TAVI+PCI
or isolated TAVI (29).
STUDY LIMITATIONS
Given the observational design, many limitations must be consid-
ered. Our study included several patient subsets (i.e., patients with
previously treated CAD, untreated CAD who underwent staged or
concomitant PCI) with no information being provided about the
completeness of revascularization. The impact of residual myocar-
dial at risk cannot be evaluated. The treatment strategy was based
on the Heart Team, taking into consideration an estimative of
the myocardial tissue at risk, and the technical complexity. No
ischemia and viability imaging tests were performed. Limitations
are also due to its monocentric design; however, this aspect gives a
clear picture of the impact of a homogeneous treatment strategy.
CONCLUSION
In severe symptomatic AS who undergo TAVI, CAD adversely
impacts long-term mortality, but not increases the periprocedure
risks. In selected patients, PCI before TAVI might be a reason-
able revascularization option. Further randomized studies are
needed to evaluate the best treatment strategy for CAD, the ben-
efits of revascularization, and the impact of non-revascularized
myocardium in outcomes after TAVI. The role of FFR analysis and
ischemia imaging tests needs to be explored in this setting.
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